Teva announces successful migraine medication study
A medication to prevent migraines yielded positive results in a final experimental trial, the last step before having enough data to be submitted to the Food and Drug Administration for approval. Teva Pharmaceuticals announced Wednesday the successful completion of their Phase III HALO study of fremanezumab, a medication used to prevent migraines. “Migraine is a serious,…
Utah Standard News depends on the support of readers like you.
Good Journalism requires time, expertise, passion and money. We know you appreciate the coverage here. Please help us to continue as an alternative news website by becoming a subscriber or making a donation. To learn more about our subscription options or make a donation, click here.
To Advertise on UtahStandardNews.com, please contact us at: ed@utahstandardnews.com.
Comments - No Responses to “Teva announces successful migraine medication study”
Sure is empty down here...